Platelet-Type von Willebrand Disease: Complex Pathophysiology and Insights on Novel Therapeutic and Diagnostic Strategies

Abstract

von Willebrand disease (VWD) is the most common well-studied genetic bleeding disorder worldwide. Much less is known about platelet-type VWD (PT-VWD), a rare platelet function defect, and a “nonidentical” twin bleeding phenotype to type 2B VWD (2B-VWD). Rather than a defect in the von Willebrand factor (VWF) gene, PT-VWD is caused by a platelet GP1BA mutation leading to a hyperaffinity of the glycoprotein Ibα (GPIbα) platelet surface receptor for VWF, and thus increased platelet clearing and high-molecular-weight VWF multimer elimination. Nine GP1BA gene mutations are known. It is historically believed that this enhanced binding was enabled by the β-switch region of GPIbα adopting an extended β-hairpin form. Recent evidence suggests the pathological conformation that destabilizes the compact triangular form of the R-loop—the GPIbα protein's region for VWF binding. PT-VWD is often misdiagnosed as 2B-VWD, even the though distinction between the two is crucial for proper treatment, as the former requires platelet transfusions, while the latter requires VWF/FVIII concentrate administration. Nevertheless, these PT-VWD treatments remain unsatisfactory, owing to their high cost, low availability, risk of alloimmunity, and the need to carefully balance platelet administration. Antibodies such as 6B4 remain undependable as an alternative therapy due to their questionable efficacy and high costs for this purpose. On the other hand, synthetic peptide therapeutics developed with In-Silico Protein Synthesizer to disrupt the association between GPIbα and VWF show preliminary promise as a therapy based on in vitro experiments. Such peptides could serve as an effective diagnostic technology for discriminating between 2B-VWD and PT-VWD, or potentially all forms of VWD, based on their high specificity. This field is rapidly growing and the current review sheds light on the complex pathology and some novel potential therapeutic and diagnostic strategies.

Keywords

platelet-type von Willebrand disease - GPIbα - VWF - platelet aggregation - in-silico - synthetic peptides

^* These authors contributed equally to this article.

Publikationsverlauf

Artikel online veröffentlicht:
27. August 2024

• References

• 1 Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011; 37 (05) 464-469
• 2 Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin Thromb Hemost 2007; 33 (08) 780-786
• 3 Takahashi H, Nagayama R, Hattori A, Ihzumi T, Tsukada T, Shibata A. Von Willebrand disease associated with familial thrombocytopenia and increased ristocetin-induced platelet aggregation. Am J Hematol 1981; 10 (01) 89-99
• 4 Weiss HJ, Meyer D, Rabinowitz R. et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982; 306 (06) 326-333
• 5 Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982; 60 (03) 790-794
• 6 Lopez JA, Chung DW, Fujikawa K, Hagent FS, Papayannopoulout T, Rotht GJ. Cloning of the alpha chain of human platelet glycoprotein Ib: a transmembrane protein with homology to leucine-rich C2-glycoprotein. Biochemistry 1987; 84: 5615-5619
• 7 Woods AI, Sanchez-Luceros A, Bermejo E. et al. Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease. Semin Thromb Hemost 2014; 40 (02) 151-160
• 8 Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet glycoprotein lb in platelet-type von Willebrand disease (blood platelets/platelet disorders/genetic diseases). Proc Natl Acad Sci USA 1991; 88: 4761-4765 Accessed August 1, 2024 at: https://www.pnas.org
• 9 Matsubara Y, Murata M, Sugita K, Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost 2003; 1 (10) 2198-2205
• 10 Enayat S, Ravanbod S, Rassoulzadegan M. et al. A novel D235Y mutation in the GP1BA gene enhances platelet interaction with von Willebrand factor in an Iranian family with platelet-type von Willebrand disease. Thromb Haemost 2012; 108 (05) 946-954
• 11 Takahashi H, Murata M, Moriki T. et al. Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 1995; 85 (03) 727-733
• 12 Othman M, Notley C, Lavender FL. et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 2005; 105 (11) 4330-4336
• 13 Bury L, Falcinelli E, Kuchi Bhotla H. et al. A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD. Blood Adv 2022; 6 (07) 2236-2246
• 14 Lavenu-Bombled C, Guitton C, Dupuis A. et al. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B “Malmö/New York” von Willebrand disease. Thromb Haemost 2016; 116 (06) 1070-1078
• 15 Monteiro C, Gonçalves A, Pereira M, Lau C, Morais S, Santos R. A new case of platelet-type von Willebrand disease supports the recent findings of gain-of-function GP1BA variants outside the C-terminal disulphide loop enhances affinity for von Willebrand factor. Br J Haematol 2023; 203 (04) 673-677
• 16 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?. Semin Thromb Hemost 2008; 34 (01) 113-127
• 17 Hamilton A, Ozelo M, Leggo J. et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost 2011; 105 (03) 501-508
• 18 Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol 2008; 30 (02) 91-94
• 19 Bury L, Malara A, Momi S, Petito E, Balduini A, Gresele P. Mechanisms of thrombocytopenia in platelet-type von Willebrand disease. Haematologica 2019; 104 (07) 1473-1481
• 20 Othman M, Gresele P. Guidance on the diagnosis and management of platelet-type von Willebrand disease: a communication from the Platelet Physiology Subcommittee of the ISTH. J Thromb Haemost 2020; 18 (08) 1855-1858
• 21 Bury L, Falcinelli E, Mezzasoma AM, Guglielmini G, Momi S, Gresele P. Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway. Haematologica 2022; 107 (07) 1643-1654
• 22 Kaur H, Corscadden K, Ware J, Othman M. Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease. Thromb Haemost 2017; 117 (03) 543-555
• 23 Othman M, Kaur H, Favaloro EJ. et al; Subcommittees on von Willebrand Disease and Platelet Physiology. Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. J Thromb Haemost 2016; 14 (02) 411-414
• 24 Othman M. Platelet-type von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev 2011; 25 (04) 147-153
• 25 Giannini S, Cecchetti L, Mezzasoma AM, Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010; 95 (06) 1021-1024
• 26 Kaur H, Ozelo M, Scovil S, James PD, Othman M. Systematic analysis of bleeding phenotype in PT-VWD compared to type 2B VWD using an electronic bleeding questionnaire. Clin Appl Thromb Hemost 2014; 20 (08) 765-771
• 27 Tischer A, Machha VR, Moon-Tasson L, Auton M. Platelet-type von Willebrand disease: Local disorder of the platelet GPIbα β-switch drives high-affinity binding to von Willebrand factor. J Thromb Haemost 2019; 17 (12) 2022-2034
• 28 Othman M, Lopez JA, Ware J. Platelet-type von Willebrand disease update: the disease, the molecule and the animal model. Expert Rev Hematol 2011; 4 (05) 475-477
• 29 Othman M, Emsley J. Platelet-type von Willebrand disease: toward an improved understanding of the “sticky situation”. Semin Thromb Hemost 2014; 40 (02) 146-150
• 30 Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand Disease. Semin Thromb Hemost 2016; 42 (02) 133-146
• 31 Solves Alcaina P. Platelet transfusion: and update on challenges and outcomes. J Blood Med 2020; 11: 19-26
• 32 Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012; 79 (04) 237-245
• 33 Fontayne A, Vanhoorelbeke K, Pareyn I. et al. Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost 2006; 96 (05) 671-684
• 34 Fontayne A, De Maeyer B, De Maeyer M, Yamashita M, Matsushita T, Deckmyn H. Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. J Biol Chem 2007; 282 (32) 23517-23524
• 35 Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495-497
• 36 Lu RM, Hwang YC, Liu IJ. et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020; 27 (01) 1
• 37 Chen Z, Wang X, Chen X. et al. Accelerating therapeutic protein design with computational approaches toward the clinical stage. Comput Struct Biotechnol J 2023; 21: 2909-2926
• 38 Davies JA, Ireland S, Harding S, Sharman JL, Southan C, Dominguez-Monedero A. Inverse pharmacology: approaches and tools for introducing druggability into engineered proteins. Biotechnol Adv 2019; 37 (08) 107439
• 39 Crook ZR, Nairn NW, Olson JM. Miniproteins as a powerful modality in drug development. Trends Biochem Sci 2020; 45 (04) 332-346
• 40 Hosseinzadeh P, Bhardwaj G, Mulligan VK. et al. Comprehensive computational design of ordered peptide macrocycles. Science 2017; 358 (6369): 1461-1466 Accessed August 1, 2024 at: https://www.science.org
• 41 Pitre S, Dehne F, Chan A. et al. PIPE: a protein-protein interaction prediction engine based on the re-occurring short polypeptide sequences between known interacting protein pairs. BMC Bioinformatics 2006; 7: 365
• 42 Neduva V, Linding R, Su-Angrand I. et al. Systematic discovery of new recognition peptides mediating protein interaction networks. PLoS Biol 2005; 3 (12) e405
• 43 Kazmirchuk TDD, Bradbury-Jost C, Withey TA. et al. Peptides of a feather: how computation is taking peptide therapeutics under its wing. Genes (Basel) 2023; 14 (06) 1194
• 44 Wu K, Bai H, Chang YT. et al. De novo design of modular peptide-binding proteins by superhelical matching. Nature 2023; 616 (7957): 581-589
• 45 Lewis AL, McEntee N, Holland J, Patel A. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv Transl Res 2022; 12 (01) 1-6
• 46 Burnside D, Schoenrock A, Moteshareie H. et al. In silico engineering of synthetic binding proteins from random amino acid sequences. iScience 2019; 11: 375-387
• 47 Dick K, Pattang A, Hooker J. et al. Human-soybean allergies: elucidation of the seed proteome and comprehensive protein-protein interaction prediction. J Proteome Res 2021; 20 (11) 4925-4947
• 48 Schoenrock A, Burnside D, Moteshareie H. et al. Evolution of protein-protein interaction networks in yeast. PLoS ONE 2017; 12 (03) e0171920
• 49 Pitre S, Hooshyar M, Schoenrock A. et al. Short co-occurring polypeptide regions can predict global protein interaction maps. Sci Rep 2012; 2: 239
• 50 Dick K, Dehne F, Golshani A, Green JR. Positome: A Method for Improving Protein-Protein Interaction Quality and Prediction Accuracy. Paper presented at: 2017 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology; August 23–25, 2017. pp. 1–8.
• 51 Pitre S, North C, Alamgir M. et al. Global investigation of protein-protein interactions in yeast Saccharomyces cerevisiae using re-occurring short polypeptide sequences. Nucleic Acids Res 2008; 36 (13) 4286-4294
• 52 Dick K, Samanfar B, Barnes B. et al. PIPE4: Fast PPI predictor for comprehensive inter- and cross-species interactomes. Sci Rep 2020; 10 (01) 1390
• 53 Schoenrock A, Burnside D, Moteshareie H. et al. Engineering Inhibitory Proteins with InSiPS: The In-Silico Protein Synthesizer. Paper presented at: International Conference for High Performance Computing, Networking, Storage and Analysis, SC. Vol 15–20; November 2015. IEEE Computer Society; 2015:1–11.
• 54 Schoenrock A, Dehne F, Green JR, Golshani A, Pitre S. MP-PIPE: A Massively Parallel Protein-Protein Interaction Prediction Engine. Paper presented at: Supercomputing Conference (SCC). Association for Computing Machinery; 2011:402.
• 55 Mehranfar A, Ghadiri N, Kouhsar M, Golshani A. A Type-2 fuzzy data fusion approach for building reliable weighted protein interaction networks with application in protein complex detection. Comput Biol Med 2017; 88: 18-31
• 56 Barnes B, Karimloo M, Schoenrock A. et al. Predicting novel protein- protein interactions between the HIV-1 virus and Homo sapiens. Paper presented at: 2016 IEEE EMBS International Student Conference (ISC); 2016:1–4.
• 57 Schoenrock A, Samanfar B, Pitre S. et al. Efficient prediction of human protein-protein interactions at a global scale. BMC Bioinformatics 2014; 15 (01) 383
• 58 Jessulat M, Pitre S, Gui Y. et al. Recent advances in protein-protein interaction prediction: experimental and computational methods. Expert Opin Drug Discov 2011; 6 (09) 921-935
• 59 Amos-Binks A, Patulea C, Pitre S. et al. Binding site prediction for protein-protein interactions and novel motif discovery using re-occurring polypeptide sequences. BMC Bioinformatics 2011; 12 (225): 225
• 60 Kazmirchuk T, Dick K, Burnside DJ. et al. Designing anti-Zika virus peptides derived from predicted human-Zika virus protein-protein interactions. Comput Biol Chem 2017; 71: 180-187
• 61 Hajikarimlou M, Hooshyar M, Moutaoufik MT. et al. A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S. NAR Genom Bioinform 2022; 4 (03) lqac058
• 62 Kazmirchuk TDD, Othman M, Golshani A. Using AI to generate peptide therapeutics against the VWF-GP1bα interaction. Int Soc Lab Hematol 2023; 45: 3-137